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Chemicals associated with anti-inflammatory biological signaling pathways are 
known to be effective methods of alleviating the symptoms for numerous diseases and 
medical conditions, including diabetes. Recently, an increasing number of studies are 
analyzing biological signaling compounds in the context of having the potential to directly 
stimulate regeneration of pancreatic β-cells. Few efforts have been successful in 
demonstrating and characterizing the relationship between compounds associated with anti-
inflammatory pathways and the proliferation and regeneration capability of β-cells. This 
study aimed to test the effects of chemicals with anti-inflammatory effects on the up-
regulation of insulin regeneration in zebrafish embryos. The ultimate goal was to discover 
specific anti-inflammatory drugs that have the potential to treat diabetes by directly 
increasing the size and insulin-secreting functionality of the β-cell mass, as well as to 
determine their mechanisms of action. It was discovered that the small molecule BX-795, 
which acts as an anti-inflammatory agent and inhibits the catalytic activity of the protein 
kinases tank-binding kinase 1 (TBK1) and Inhibitor of nuclear factor kappa-B kinase subunit 
epsilon (IKKε) of the toll-like receptor biological signaling pathway, has great potential as a 
successful inducer of β-cell regeneration following ablation of β-cells. This compound and 








Diabetes is an endocrine disease characterized by abnormally high blood glucose levels. 
It is the seventh leading cause of mortalities and increases chance of death by 50% in adults in 
the United States. This statistic does not include deaths caused by complications triggered by 
diabetes, such as heart disease (which is the leading cause of death in the United States), eye 
complications, kidney disease, and neuropathy1. Type I diabetes is a genetically inherited 
autoimmune disease that causes destruction of insulin-released β-cells in the pancreas, leading to 
insulin deficiency and high blood glucose levels2. Type II diabetes is caused by insulin-
resistance, which involves impaired detection of the normal levels of insulin being produced by 
β-cells and therefore an increased demand for insulin via compensatory β-cell function3.  
Currently, commonly diabetes-specific treatments include insulin supplements and the 
oral drugs metformin, pioglitazone, and sitagliptin. Each of these treatments has a unique 
mechanism of action associated with biological signaling pathways, yet none has its most potent 
effect on targeting the underlying cause of diabetes by increasing β-cell function4 5 6. A novel 
idea for treatment of diabetes, particularly Type I diabetes, is reversing its underlying cause via 
stimulation of β-cell proliferation and regeneration. Studies on the proliferation and 
differentiation of β-cells that utilize model organisms in vivo show great potential for reversing 
the outcome of β-cell death in humans. The zebrafish Danio rerio is an effective model organism 
for such studies because it is a vertebrate that has externally developing embryos, it can be 
mutated easily, and it has rapid embryonic development (Figure 1).  Additionally, the optical 
clarity of zebrafish embryos allows for visualization of the organism’s vital organs through its 
developmental stages utilizing fluorescent protein tagging7. The structure and function of the 
 
2 
zebrafish hepatopancreatic system closely resemble those of humans; therefore, regenerative 
responses of the zebrafish to chemical and physical stimuli show great potential in studies of 













It is known that drugs that exert anti-inflammatory effects on biological signaling 
pathways have the potential to reverse the incidence and delay the onset of Type II diabetes. 
However, the specific relationship between anti-inflammation and the regenerative properties of 
β-cells is yet to be established.  This study aims to test the effect of chemicals with anti-
inflammatory effects on the up-regulation of insulin regeneration in zebrafish embryos. The 
ultimate aim is to identify anti-inflammatory drugs that have the potential to treat diabetes by 
directly increasing the size and insulin-secreting functionality of the β-cell mass. 
 
Figure 1: Images of zebrafish. a) Zebrafish embryo in the first 24 hpf; b) Zebrafish embryo 






REVIEW OF LITERATURE 
Chemicals associated with anti-inflammatory biological signaling pathways are known to 
be effective methods of alleviating the symptoms for numerous diseases and medical conditions, 
including diabetes. Recently, an increasing number of studies are analyzing biological signaling 
compounds in the context of having the potential to directly stimulate regeneration of pancreatic 
β-cells. So far few efforts have been successful in demonstrating and characterizing the 
relationship between compounds associated with anti-inflammatory pathways and the 
proliferation and regeneration capability of β-cells9. 
Diabetes involves progressive β-cell death, which prevents the production of adequate 
levels of insulin to control serum glucose levels. An expanding body of evidence suggests that 
inflammation plays a significant role in the onset and progression of the disease. Many anti-
inflammatory drugs with their most pronounced effects on non-diabetes ailments, including 
angiotensin-converting-enzyme inhibitors, metformin, aspirin, and thiazolidinediones, are known 
to the reduce the risk and alleviate the symptoms of Type II diabetes10. However, each of these 
drugs has a distinct mechanism of action that is not necessarily specific to targeting pancreatic β-
cells.  
Among the most promising anti-inflammatory compounds tested for effects on diabetes 
reversal and β-cell regeneration is the inhibitory neurotransmitter gamma amino-butyric acid 
(GABA). Numerous studies have shown that GABA also exerts significant function in the 
immune system and pancreatic islets of Langerhans, and it particularly acts on T-cells and 
macrophages to produce its anti-inflammatory effects11. Furthermore, GABA has been 
demonstrated to promote proliferation of human β-cells in vitro12, increase DNA synthesis and 
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insulin release in the pancreatic cell line INS-113, regulate insulin secretion in response to 
fluctuating glucose levels, and reduce apoptosis in cultured cells14. GABA has been found to 
inhibit the activation of the transcription complex NF-kB in islet cells and more specifically to 
increase the expression of the SIRT1 gene to reduce apoptosis, a novel pathway of research for 
diabetes therapy15. 
Furthermore, a recent in vivo study found that compounds associated with the adenosine 
signaling pathway promote regeneration of β-cells16. In this study, over 5000 different chemical 
compounds associated with different biological signaling pathways were tested for their effects 
on β-cells in zebrafish embryos that were double positive for Tg(ins:CFP-NTR) and 
Tg(ins:Kaede). Compounds that are both agonists and antagonists of adenosine signaling were 
found to increase the size of the β-cell mass following ablation, the most potent of these being 
the adenosine agonist 5’-N-ethylcarbox-amidoadenosine (NECA)16. These chemicals were 
confirmed to increase regeneration rather than proliferation of surviving β-cells by 
photoconversion of Tg(ins:Kaede), as well proven to be successful in suppressing free glucose 
levels. NECA also had a modest effect on β-cell formation during normal development, without 
ablation8. Adenosine is an anti-inflammatory agent known to regulate tissue damage and repair17; 
therefore, it may impact the proliferation that results from the regenerative response to β-cell 
death. Furthermore, there is a relationship between the A2b gene locus and elevation of pro-
inflammatory mediators that contribute to increased insulin resistance18. The study concluded 
that the anti-inflammatory pathways associated with adenosine signaling impact β-cell mass size 
and functionality, and stated that adenosine signaling may have several different mechanisms by 
which it can promote regeneration of β-cells8.  
It is known that proliferation of β-cells is induced by related classes of nucleotides and 
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nucleosides, including adenosine triphosphate (ATP) and adenosine, binding to receptor loci 
such as A2a and A2b. This sequentially causes an increase in cyclic AMP (cAMP) levels, 
activates protein kinase A, phosphorylates cAMP response element-binding protein, and binds to 
cAMP response elements in promoter regions of target genes to directly regulate transcription19. 
Although it is known that the binding receptors involved with proliferation are associated with 
inflammatory markers, a precise mechanistic relationship between anti-inflammation and β-cell 
proliferation is yet to be discovered.  
The drugs metformin, pioglitazone, and sitagliptin are currently common treatments for 
Type II diabetes. Each of these medications has a distinct mechanism of action, yet none have 
their most potent effect on increasing β-cell function20 21 22. Nonetheless, studies have shown that 
each of them has an up-regulatory effect on markers of β-cell function in patients with Type II 
diabetes23 and that each has an anti-inflammatory effect from their mechanisms24 25 26. 
Furthermore, other commonly prescribed anti-inflammatory drugs, particularly statins for 
hypercholesterolemia and ACE inhibitors for hypertension, also have anti-diabetic properties27. 
Few findings exist that analyze the effects of these drugs on β-cell mass size and hence their 
applicability in directly treating Type I diabetes.  
One of the most useful and high-throughput methods of studying size and function of β-
cells is by utilizing transgenic zebrafish. One powerful system to utilize is the double transgenic 
Tg(ins:CFP-NTR);Tg(ins:Kaede). Tg(ins:CFP-NTR) contains a fusion protein of cyan 
fluorescent protein (CFP) and the enzyme nitroreductase under the insulin promoter. 
Nitroreductase (NTR) is an enzyme derived from E. coli that converts the compound 
metronidazole (MTZ) to a toxic product, which results in apoptosis of insulin producing β-cells. 
The ablated cells, upon removal of MTZ, have the ability to recover from ablation. 
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Tg(ins:Kaede) expresses the Kaede protein, which originates from stony coral and is 
characterized by very bright green fluorescence. Kaede also has the property of being 
photoconvertible. Upon ultraviolet irradiation, the green color of the protein can be converted to 
red (Figure 2). 
28 
In a preliminary study, the 73 compounds of the Selleck stem cell library were tested for 
their effects on the regeneration capability of the β-cell mass in zebrafish embryos. This was 
assessed utilizing the Tg(ins:CFP-NTR);Tg(ins:Kaede)	  system	  with	  MTZ	  treatment. The 
nitroreductase protein labeling of the β-cells allows for ablation, or death, of the β-cell mass 
upon treatment with the compound metronidazole (MTZ). It was discovered that the small 
molecule BX-795, which acts as an anti-inflammatory agent and inhibits the catalytic activity of 
the protein kinases tank-binding kinase 1 (TBK1) and Inhibitor of nuclear factor kappa-B kinase 
subunit epsilon (IKKε) of the toll-like receptor signaling pathway, has been found to have an 
upregulatory effect on the regeneration of β-cells in the zebrafish model organism. The drug 
amlexanox, an asthma drug that is a TBK1 and IKKε inhibitor, has been found to alleviate 
obesity and obesity-induced health problems in mice and is currently being investigated29. So far 
few other studies have honed in on the effect of this signaling pathway on diabetes causation and 






treatment. None have analyzed the effect of inhibition of TBK1 and IKKε on the functionality of 
β-­‐cells.  
With the wealth of knowledge that exists regarding the effect of inflammation on 
diabetes, it is clear that a significant relationship exists between inflammation and β-cell viability 
and functionality. A step forward toward a clearer understanding of this relationship is the 
discovery of a new biological mechanism that relates these two.  
 The proposed study further addresses the necessity and potential for diabetes treatments 
that involve stimulating the health and action of β-cells by examining the effect of anti-
inflammatory compounds on the proliferation and regeneration capacity of β-cells in vivo using 
zebrafish embryos. It aims to test the effect of a variety of compounds, particularly those that 
inhibit the function of TBK1 and IKKε, on the regeneration capacity of ablated β-cells and the 
normal development of β-cells.  
If the compounds tested prove to be consistently successful in increasing the size and 
function of the β-cell mass in zebrafish, the discovery could pave the way for new studies and 
therapies that target these parts of the toll-like signaling pathway to counter the underlying cause 
of diabetes. Furthermore, this study aims to test the effect of many commonly used anti-
inflammatory diabetes drugs on β-cell regeneration, to find potential links between the 






GENERAL CHEMICAL SCREENING PROTOCOL 
In the majority of the experiments in this study, the nitroreductase-metronidazole (NTR-
MTZ) system was applied to the double transgenic Tg(ins:CFP-NTR);Tg(ins:Kaede). An 








Reagents Egg water was prepared by combining double-deionized H2O, calcium sulfate 
obtained from Acros Organics, Instant Ocean, and methylene blue. Phenylthiourea (PTU) was 
obtained from Sigma Aldrich. The initial set of 73 compounds tested was the Stem Cell Library 
obtained from Selleck Chemicals. Dimethyl sulfoxide (DMSO) was obtained from Fisher 
Scientific (BP231-1). The metronidazole (MTZ) was obtained from Sigma Life Science (M1547-
25G). 
Mating of zebrafish to yield transgenic embryos The procedure for chemical screening 
followed a 7-day timeline (Figure 3).  On average, each week, between ten and twelve matings 
were set up between zebrafish that were double-positive for Tg(ins:CFP-NTR);Tg(ins:Kaede) by  
 
Figure 3: Summary of general timeline for chemical screening. 
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placing one female with two males or two females with one male in a mating tank to increase 
chances of productivity of the cross. The next morning, the tanks were checked for presence of 
eggs. On average, about half the crosses set up for each round were productive; however, the 
fertility of the fish was highly dependent on their age, diet, and health condition. The eggs were 
harvested, cleaned, sorted into petri dishes with 80 eggs and approximately 20 mL of egg water 
each, and incubated at 35°C for the next 24 hours.  
Prevention of pigmentation At 1 day post fertilization (dpf), the petri dishes were each 
cleaned, by replacing the egg water and removing dead embryos. A 20X solution of PTU (1 mL) 
was added to each of the plates to prevent pigmentation buildup in the embryos, and the plates 
were incubated at 35°C for the next 48 hours.   
Sorting of double positive embryos and MTZ ablation At 3 dpf, the embryos were 
viewed under the Leica M205 fluorescence microscope under both the GFP and CFP channels to 
separate embryos that were double positive (the CFP and GFP were both visible, Figure 4). To 
ablate the β-­‐cells, MTZ solution (15 mM) was prepared by combining 20 mL of egg water, 20 
µL DMSO, 1 mL 20X PTU, and 0.1 g of solid MTZ per petri dish containing approxomiately 60 
embryos. The bottle in which the solution was prepared was wrapped in aluminum foil to prevent 
light-sensitive MTZ from losing its activity. The MTZ solution was dispensed into the petri 



















Confirmation of ablation and treatment of compounds At 4 dpf, the embryos were  
viewed under the GFP channel of the fluorescent microscope to sort for fully ablated embryos, 
which had no GFP visible (Figure 5). The MTZ was removed from the water of the embryos by 
washing the embryos 3 to 4 times with egg water. The embryos were sorted into 24-well plates 
containing approximately 6 embryos per well in 400 µL of 1X PTU.  A chemical from the 
Selleck stem cell library dissolved in DMSO at a concentration of 25 µM was added to each 
well. Wells containing embryos exposed to DMSO served as the negative control and wells 
containing embryos exposed to LY411575, an inhibitor of the Notch signaling pathway, at a 




Figure 4: Images of double positive embryo at 3 dpf prior to addition of MTZ. The embryo 
under the bright field, cyan fluorescent protein filter (Tg(ins:CFP-NTR)), and green fluorescent 
protein filter (Tg(ins:Kaede)) are displayed. A bright dot representing β-cell mass is clearly 












Visualizing regeneration Forty-eight hours later, effects of the compounds on 
regeneration of β-­‐cells	  was observed by comparing the relative size of the β-­‐cell	  mass of the fish 
exposed to the test conditions to those exposed to both the negative control and the positive 
control. Chemicals that caused the embryos to show a significant increase in the size of the β-­‐cell	  
mass as visible under the fluorescence microscope were recorded. Photos were taken using a 
Leica DFC425 C digital camera and Leica software. Compounds that were questionable or 
hopeful for increased insulin regeneration were re-screened. An overview of this process is 
displayed in Figure 3.  
SUPPLEMENTAL STEPS TO CHEMICAL SCREENING PROTOCOL 
Dilution of chemical compounds The chemical compounds utilized in this study were 
obtained in powder form. Therefore, it was necessary to dilute them in DMSO to utilize them as 
treatments for the embryos. Each chemical compound stock solution was prepared at a 
concentration of 10 mM. The initial working concentration utilized for the treatments was 25 
µM. The working concentrations were either increased or decreased depending on viability 
Figure 5: Images of double positive embryo 4 dpf following MTZ-mediated ablation. The 
embryo under the bright field, cyan fluorescent protein filter (Tg(ins:CFP-NTR)), and green 
fluorescent protein filter (Tg(ins:Kaede)) are displayed. A bright dot representing β-cell mass is 
no longer visible under either of the fluorescent filters. 
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results seen in experiments or based upon concentrations utilized in literature. 
 
Photoconversion of Tg(insulin:kaede) MTZ treatment (15 mM) does not always ablate 
all of the β-­‐cells	  following a 24-hour treatment time, and treating the embryos for longer than 24 
hours tends to decrease the viability of the embryos. To track β-­‐cells	  that were not fully ablated 
following MTZ treatment, the GFP of the Kaede protein was converted from green to red prior to 
MTZ treatment by exposure to ultraviolet radiation. With photoconversion, all of the remaining 
cells following MTZ treatment are red, while those that regenerate are green. This allows for 
clearer distinguishing between surviving and regenerated cells, and therefore allows for 
determination of whether increased β-­‐cell	  mass by certain drugs was a result of survival or 
regeneration. The compounds that were observed to increase regeneration of β-­‐cells	  were re-
tested following photoconversion of the Kaede protein marking the insulin cells of the zebrafish 
embryos. The general chemical screening procedure was followed through 3 dpf. Double-
positive embryos were sedated by adding 3-aminobenzoic acid ethyl ester (tricaine) solution at 
pH 7 to the surrounding egg water. The embryos were placed into a 35 mm glass-bottom petri 
dish. Using the Zeiss LSM 700-405 confocal microscope, the focus was adjusted to β-­‐cell	  mass 
with Kaede expression, particularly to the plane demonstrating the greatest area and brightest 
expression of the protein. The boundary of the β-­‐cell	  mass was selected and a 405 nm UV light 
Compound Name Function Source Working concentration 
BX-795 TBK1/ IKKε inhibitor Selleck Chemicals 25 mM 
Amlexanox TBK1/ IKKε inhibitor Sigma Aldrich 25 mM 
CYT-387 TBK1/ IKKε inhibitor Selleck Chemicals 25 mM 
MRT67307 TBK1/ IKKε inhibitor Calbiochem 25 mM 
NECA Adenosine A1 and A2 
receptor 
Tocris Biosciences 25 mM 
Table 1: List of compounds stock solutions prepared 
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was utilized for the bleaching of this region. The exposed cells transformed to a red color. If any 
yellow spots persisted, indicating the overlap of green and red cells, the bleaching experiment 
was performed a second time, but using fewer cycles to minimize damage to the embryo. The 
general chemical screening protocol was continued as written. Following MTZ treatment, 
compound treatment, and regeneration, the newly formed cells that originated from the cells that 
persisted following MTZ treatment were yellow in color under both the GFP and DSR filters 
(due to the overlap of green and red cells), while the regenerated cells that did not originate from 
















Figure 6: Photoconversion to Tg(ins:Kaede) embyros. a) Reaction that causes 
photoconversion. The reactant is a red chromophore, which is cleaved to form a red 
chromophore. b) Confocal image of embryo prior to photoconversion, showing GFP labeling 
of β-cells. c) Confocal image of embryo following photoconversion of GFP, showing RFP 




























 Proliferation assay EdU obtained from the Click-iT® EdU Alexa Fluor ® 647 Imaging 
Kit from Invitrogen™ was utilized. At 4 dpf following MTZ treatment and sorting of fully-
ablated embryos, EdU in DMSO (7 µM) was added to the 24-well plates containing the embryos 
along with the compounds. Following a 48 hour regeneration period at 35°C, EdU was 
incorporated into the regenerated cells. Immunostaining was performed to visualize the number 
of cells that incorporated EdU under the Zeiss LSM 700-405 confocal microscope. 
 Fixation of embryos At 6 dpf, following the regeneration period, select embryos were 
saved for staining and confocal imaging to obtain accurate cell counts for statistical analysis, as 
well as high-resolution images. Approximately 10 embryos were placed into a 2 mL 
microcentrifuge tube and all water was removed from the tube. PEM fixation buffer (0.1 M 
PIPES pH 6.95, 2 mM EGTA, 1 mM MgSO4, 945 µL) and 2% formaldehyde in PEM (55 µL) 
were added to the tube. The embryos were able stored at -20°C for up to 2 weeks for confocal 
visualization. After this time period, fluorescence proteins begin to degrade and therefore lose 





RESULTS AND DISCUSSION 
Preliminary chemical screening results Chemical screening of the Selleck stem cell 
library consistently yielded one compound as “very hopeful” for β-­‐cell	  regenerative properties. 
The small molecule BX-795 (Figure 7) showed much larger β-­‐cell	  mass upon treatment with 25 
µM of the compound, compared to the negative control. This compound was retested ten times 
throughout the course of the screening by viewing β-­‐cell	  mass size under the GFP filter (Figure 
8). Approximately 80% of the embryos treated with BX-795 were found to have a β-­‐cell	  mass 
size that appeared to be between the size of the negative control and the positive control 
following 48 hours of treatment. BX-795 is associated with anti-inflammation, consistent with 
findings in a similar study by Andersson et al30. It functions by inhibiting the activation of 
TANK-binding kinase 1 (TBK-1) and Inhibitor of nuclear factor kappa-B kinase subunit epsilon 
(IKKε), which inhibits the Toll-like receptor signaling pathway and therefore inhibits activation 
of the NFκB signaling pathway. These results are consistent with and appear to provide further 
insight previous findings that show that inhibitors of these protein kinases improve obesity-
related metabolic dysfunctions, particularly insulin resistance and tissue inflammation31. This 




















Figure 7: Chemical structure BX-795. The compound has a chemical formula of C23H26IN7O2S 














Figure 8: Preliminary results. a) First trial of embryos treated with DMSO, positive control 
compound, and compound 4b (BX-795) at 6 dpf under green fluorescent protein filter.  A 
bright dot representing regeneration of β-cell mass is present in each of these embryos. The 
three trials for BX-795 shown are representative of repeated results showing a visibly larger 
regenerated β-cell mass for embryos treated with BX-795, compared to the negative control 
DMSO. The sizes of these cell masses are smaller than those of embryos treated with the 
positive control compound LY411575, but are closer to the size of this positive control than 
that of the negative control. b) Second trial of embryos treated with DMSO, positive control 
compound, and compound 4b (BX-795) at 6 dpf under green fluorescent protein filter. A bright 
dot representing regeneration of β-cell mass is present in each of these embryos. The results are 






BX-795 increases regeneration rather than survival of β-cells To determine whether the 
results seen in the preliminary study are caused by BX-795 promoting of regeneration of new β-
cells rather than survival of β-cells following MTZ treatment, the fate of β-cells was tracked by 
labeling. The GFP characteristic of the kaede protein in Tg(ins:Kaede) embyros was 
photoconverted from green to red by exposing the β-cells to UV light at 3 dpf, prior to treating 
the embryos with MTZ. The embryos were treated for the next 48 hours with MTZ to ablate the 
β-cells, and following ablation the embryos were treated with BX-795. β-cells that survived the 
ablation appeared yellow, due to overlap of expression of both green and red kaede protein, 
while the cells β-cells that were newly regenerated only appeared green. It was found that the 
size of the green β-cell mass was consistently larger for compounds exposed to BX-795 
compared to those exposed to the control. When yellow cells were present, the size of this cell 
mass was consistently small for all treatment groups (Figures 9-10). Additionally, the size of the 
yellow cell mass did not appear increased for the BX-795 treatment group. Based upon these 










Figure 9: BX-795 promotes increase in number of β-cells following ablation. These images, 
obtained using the Zeiss LSM 700-405 confocal microscope, show the effect of BX-795 on β-cell 
regeneration following MTZ-mediated ablation from 3 dpf to 4 dpf and chemical treatment from 4 
dpf to 6 dpf.  a) Regenerated β-cell mass of control embryo expressing Tg(ins:Kaede) at 6 dpf. 
Only a small number of cells were observed to have regenerated. b) Regenerated β-cell mass of 
embryo expressing Tg(ins:Kaede) treated with 25 µM BX-795 from 4 dpf to 6 dpf at 6 dpf. A 
visibly larger number of regenerated β-cells were observed for this treatment group compared to 





















BX-795 does not impact β-­‐cell	  regeneration during normal development The effect of 
BX-795 was tested on development of the pancreas without MTZ-induced ablation of the β-cells. 
This was performed to determine whether BX-795 causes a general increase in number of β-cells 
even without any stress having acted upon the cells or has therapeutic action that only functions 
in response to stresses, such as ablation. The general chemical screening protocol was followed, 
with compound treatment from 4-6 dpf but without ablation from 3-4 dpf. It was found that BX-
795 did not cause a significant and visible increase in the size of the β-cell mass (Figure 11). 
This gives initial evidence that BX-795 may function by restoring an optimal number of β-cells, 
rather than causing unnecessary increase in the number of β-cells beyond that which is necessary 
to maintain proper blood glucose levels. Based upon this hypothesis, BX-795 will not increase β-
Figure 10: BX-795 promotes regeneration rather than survival of β-cells. At 3 dpf, the 
Tg(ins:Kaede)-expressing β-cells were photoconverted from green to red by exposing them to 
UV light and then treated with MTZ for 24 hours. After two days of regeneration, through 6 dpf, 
β-cells that survived the MTZ ablation appeared yellow, due to overlap of red and green cells, 
while those that truly regenerated were green only.  a) Confocal images of the β-cells of a 
control embryo, which was treated with only DMSO, at 6 dpf. Only one β-cell survived ablation 
in this embryo. b) Confocal images of β-cells at 6 dpf of an embryo treated with BX-795. No β-
cells were shown to have survived ablation in this particular embryo. Consistent with Figure 9, 
the size of the β-cell mass is larger and the number of β-cells is greater for the BX-795 treated 







cell mass to levels that can cause higher-than-normal insulin levels and therefore lower-than- 






Predicted molecular significance of BX-795 The compound BX-795 is known to act as 
an anti-inflammatory agent and inhibits the catalytic activity of the protein kinases tank-binding 
kinase 1 (TBK1) and Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKKε) of the 
toll-like receptor signaling pathway, has been found to have a constructive effect on the 
regeneration of β-cells in the zebrafish model organism. Amlexanox, another TBK1 and IKKε 
inhibitor and a drug used to treat asthma that is a TBK1 and IKKε inhibitor, has been found to 
alleviate obesity and obesity-induced health problems in mice. This drug decreased insulin 
Figure 11: BX-795 exposure does not have a significant effect on size of β-cell mass during 
normal development, without ablation by MTZ. a) A control embryo, which was treated with 
DMSO only; b) First trial of treatment of embryos treated with BX-795; c) Second trial of 
embryos treated with BX-795. If the β-cells are not ablated prior to compound treatment, there is 
no significant difference in the size of the β-cell mass of the embryos treated with the control 









resistance as well as expression of inflammatory markers.30 This study deduced that increased 
activity of TBK1 and IKKε by ATP-phosphorylation is the precursor to increased activity of the 
NFκB signaling pathway in the adipose tissue and liver of obese mammals. The findings of our 
study thus far provide further evidence for these results by exhibiting that production of insulin 
may be increased by inhibition of TBK1 and IKKε. All in all, the results of this study obtained 
thusfar call for a paradigm shift toward a new method of treatment for Type I diabetes that 
involves directly targeting the β-cells to proliferate and therefore produce more insulin. 
Nonetheless, a significant amount of further testing is necessary to confirm these results and to 






The following studies are currently in progress. Results will be obtained during Summer 
2015. 
Proliferation assay with BX-795 Results from a proliferation assay is a means of 
verifying the increase in proliferation of β-cells caused by treatment with BX-795. This is a 
method of assessing whether or not selected compounds caused increase in rates of mitosis, by 
way of measuring the incorporation of 5-ethynyl-2'-deoxyuridine (EdU) into the β-cells. EdU is 
an nucleotide analog of thymine, and its incorporation into β-­‐cells	  is indication of DNA 
replication characteristic of the S phase of interphase that leads to mitosis. The incorporation can 
be visualized and quantified by staining of the β-cells and counting the number of β-cells that 
show a particular type of staining that indicates presence of EdU. A higher number of cells 
incorporating EdU in the embryos treated with BX-795 compared to those treated with the 
control would verify BX-795 has the effect of inducing mitosis and therefore increasing cell 
proliferation.    
Testing of compounds with analogous targets to those of BX-795 The compound BX-
795 is known to act as an anti-inflammatory agent and inhibits the catalytic activity of the protein 
kinases TBK1 and IKKε of the toll-like receptor signaling pathway. Three compounds that are 
also inhibitors of TBK1 and IKKε, namely Amlexanox, CYT387, and MRT67307, are being 
tested at similar working concentrations to those of BX-795 to determine if they have the same 
regenerative effect on BX-795. This experiment is intended to confirm the targets on which the 




The following experiments will be completed by my graduate mentor Jin Xu during 
Summer 2015. 
Confocal imaging and statistical analysis Visualizing the number β-cells following 
regeneration using confocal microscopy (and in some situations nuclei staining) will allow for 
accurate counting of number of β-cells regenerated. This will allow for determination of 
statistical significance of the number of β-cells regenerated as a result of treatment with BX0795 
versus treatment with the control compound. 
Effects of BX-795 on other cell types The effect of BX-795 on proliferation of cell types 
other than β-cells, including endocrine α-cells (responsible for controlling glucagon levels) and 
endocrine δ-cells (responsible for controlling somatostatin levels), as well as liver and gut cells, 
will be tested. The significance of these experiments is to determine whether BX-795 specifically 
induces proliferation of β-cells or causes a general increase in proliferation of endocrine and/or 
other types of cells. This will be tested using the chemical screening protocol above but with 
transgenic lines that express NTR in these specific cell types to allow for targeted ablation of 
these cell types. The proliferation assay will also be performed and EdU incorporation will be 
quantified to determine the effect of BX-795. 
Effects of BX-795 on β-cells in the mouse model The effect of BX-795 on β-cell 
proliferation and regeneration in mice will be tested to determine if analogous results to those 
observed in zebrafish are observed in mice. Trangenic mice will be injected with streptozotocin 
(STZ) to deplete their β-cells and the effectiveness of BX-795 in promoting regeneration of β-




conserved in mammals, which will further the potential for utilizing compounds with analogous 
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